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EDITORIAL COMMENT
A Better Survival
for Women With Heart
Failure? It’s Not So Simple…*
Ileana L. Pin˜a, MD, FACC
Cleveland, Ohio
The value of experience is not in seeing much, but in seeing
wisely.
—William Osler (1)
Good news! The incidence of heart failure (HF) in women
has dropped by one-third from the 1950s through the 1990s
but has remained unchanged in men over the same time
period (2). This decline may be due to in part to the
availability of antihypertensive medications and the in-
creased recognition of elevated blood pressure levels among
physicians, given that hypertension predominates in women
as a risk factor for HF. Another possible explanation is the
decrease in the incidence of rheumatic heart disease after the
1970s in the U.S., which had affected more women than
men (3–5).
More good news! The 30-day mortality rate among
women dropped from 18% in the 1950 to 1969 decades to
11% in 1990 to 1999. Moreover, the one- and five-year
mortality in women also declined in the years 1950 to 1999
from 28% to 24% and from 57% to 45%, respectively (2).
Therefore, women have an overall better survival than men
with HF.
See page 2128
However, that is where the good news ends. In women
diagnosed with HF in the Framingham cohort from 1990 to
1999, approximately 50% had died by five years despite an
improvement in survival rates from 1950 to 1999 (2). These
improvements in survival rates are undoubtedly due to the
advances made in HF therapy over the last 30 years.
HF PRESENTATION IN WOMEN
Information about HF in women can be acquired from
registries, from large group data (insurers/health plans),
from statistical data of large organizations, or from clinical
trials such as the Beta Blocker Evaluation of Survival Trial
(BEST) about which Ghali et al. (6) report in this issue of
the Journal. If we were only to review clinical trials, however,
the number of women would appear to barely reach one-
third of all HF patients (7–23) (Table 1). Yet in registries,
health plans, and national statistics, such as the American
Heart Association Statistics, the number of women with
HF approaches one-half of all diagnosed patients (24).
Rather than speculate on the reasons for the under-
representation of women in trials, there is a lot to be learned
from these same clinical trials.
Discrepancies between the presentation of men and
women with HF are worth noting (25). Women with HF
present at an older age and have a lower prevalence of
ischemic heart disease and previous myocardial infarction
than men and are more likely to have systemic hypertension
(26). When controlling for ischemic disease, women are less
likely to have undergone coronary bypass surgery. When
suffering a myocardial infarction, women are more likely
than men to develop HF (26,27). More women than men
with HF also have diabetes as an additional comorbidity
(28). In addition, diabetic women have two to four times the
cardiovascular mortality than women without diabetes (24).
On presentation, women with HF are more symptomatic
than men with a greater degree of edema, a third heart
sound, murmurs, and more noticeable jugular venous dis-
tension (29). In addition, health-related quality of life is low
in women who are admitted with HF when compared with
men and has a smaller improvement over the hospitalization
(30). When controlling for New York Heart Association
functional class, women have a greater impairment in daily
living activities, which usually require low level effort and,
therefore, are less functional than men (31).
In the U.S., hospitalization rates for HF have increased
from 377,000 in 1979 to 962,000 in 1999 (24). When
hospitalized for HF, women have a longer length of stay,
leading to higher costs, less involvement by cardiology
specialists, and a higher in-patient mortality (32). In the
Studies Of Left Ventricular Dysfunction (SOLVD) trials,
female gender was one of the factors associated with
hospitalization for HF and one-year mortality (28,33).
HF THERAPY IN WOMEN
Given the discrepancies of presentation, burden of disease,
etiology, and hospitalizations between men and women, it is
necessary to assess the benefits of medical therapy and its
impact on disease progression and mortality. Although HF
trials have underrepresented women, they do provide im-
portant data, in subgroup analysis, which should help
clinicians recommend therapy to their female patient pop-
ulation.
Angiotensin-converting enzyme (ACE) inhibitors. Pre-
liminary analysis of the SOLVD data suggested that women
had a lesser benefit from the ACE inhibitor, enalapril, than
the men in the treatment arm of the trial (34). A recent
meta-analysis of ACE inhibitors in both treatment and
prevention trials reported that women did benefit from
ACE inhibition in treatment trials, although the benefits
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were attenuated (35). However, a significant mortality
benefit from ACE inhibitors in prevention trials was not
noted for women. The differences, however, did not reach
statistical significance and may be attributable to the small
number of women in the trials. Although ACE inhibitors
should be the standard of care for HF patients, less women
may be receiving these agents in practice. In the Metoprolol
Extended-Release Randomized Intervention Trial in Heart
Failure (MERIT-HF), fewer women were receiving an
ACE inhibitor at entry into the trial than their male
counterparts (MERIT-HF women). This difference was
not observed in the BEST trial (36).
Beta-blockers. Beta-blockers have become important ther-
apeutic agents in patients with HF who are on ACE
inhibitors. Although the number of women in the large
beta-blocker trials with carvedilol or metoprolol succinate
(extended release) has been limited, the benefits have been
definitive in mortality reduction and equal for both men and
women (36,37).
Digoxin. In the Digitalis Investigation Group trial, digoxin
failed to show an improvement in overall survival but did
result in a reduction in hospitalization rates when compared
with placebo (23). However, a recent post-hoc analysis of
the data showed that women may have an increased risk of
death with digoxin and a smaller improvement in hospital-
ization rate (38). This difference could be due to a smaller
body mass in women and, therefore, a higher comparable
blood level of digoxin (39).
THE BEST TRIAL
Ghali et al. (6) describe the female cohort in the BEST trial.
Features of the women in BEST are consistent with those of
other reports, such as a higher ejection fraction, lower
prevalence of atrial fibrillation, and a lower presence of
ischemic disease. As in the parent trial, the women in the
bucindolol group did not have an improvement in survival
when compared with placebo. The crude mortality in
women was overall lower when compared with the men.
Nonetheless, those women with ischemic disease did not
enjoy the same survival benefits over men as those with
non-ischemic disease. The investigators should be congrat-
ulated in going beyond the simple mortality rates and
examining in more detail the women with ischemic disease.
Taken separately, women with an ischemic etiology for HF
had a different course, with a 2.5-fold increase in the risk of
death compared with a 1.5-fold increase in men. Ghali et al.
(6) offer various hypotheses for this mortality difference.
The answer is not clear but should stimulate more research
into gender differences in HF. Adams et al. (40) had already
reported that the mortality was similar for men and women
when HF was due to ischemic disease and that the mortality
benefit for women was only in the dilated cardiomyopathy
group. Their data, however, were derived from a HF clinic
experience where selection bias due to referrals could exist.
The current findings in the BEST trial confirm the obser-
vations of Adams et al. (40) in a larger number of women
enrolled in a multicenter, randomized, double-blind trial.
WHAT DOES THE FUTURE HOLD?
With the continuing increase in the prevalence of obesity
(41), the already high prevalence of smoking among
women, the prevalence of hypertension in women, and an
ever increasing number of diabetics in the U.S. (33%
increase in men and women from 1990 to 1998) (24), the
number of women with ischemic disease will only continue
to grow. Today, cardiovascular disease claims the lives of
more women than men, and the gap is widening even
further (Fig. 1). Clinicians cannot afford to be less aggres-
Table 1. Women in Heart Failure Trials
Study
Number of
Patients
Number of
Women in
Percentage of
Women in
V-HeFT-I (7) 0 0 0
V-HeFT-II (8) 0 0 0
CONSENSUS-I (9) 253 75 30
SOLVD-T (10) 2,569 504 23
SOLVD-P (11) 4,228 476 31
ELITE-I (12) 722 240 31
ELITE-II (13) 3,152 966 30
MERIT-HF (14) 3,991 451 23
CIBIS II (15) 2,647 515 20
COPERNICUS (16) 2,287 465 28
Val-HEFT (17) 5,010 1,002 20
RALES (18) 1,663 446 27
SAVE (19) 2,231 390 28
TRACE (20) 1,749 501 22
CHARM (21) 7,599 243 32
SCD HeFT (22) 2,521 580 23
DIG (23) 6,800 1,520 22.4
Total 47,422 10,907 23
CHARM Candesartan in Heart Failure-Assessment of Reduction in mortality and
morbidity; CIBIS II  Cardiac Insufficiency Bisoprolol Study II; CONSENSUS 
Cooperative North Scandinavian Enalapril Survival Study; COPERNICUS 
Carvedilol Prospective Randomized Cumulative Survival; DIG  Digitalis Investi-
gation Group; ELITE  Evaluation of Losartan in the Elderly; MERIT-HF 
Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure;
RALES  Randomized Aldactone Evaluation Study; SAVE  Survival and
Ventricular Enlargement; SCD HeFT  Sudden Cardiac Death Heart Failure Trial;
SOLVD-P  Studies of Left Ventricular Dysfunction Prevention trial; SOLVD-T
 Studies of Left Ventricular Dysfunction Treatment trial; TRACE  Trandolapril
Cardiac Evaluation; Val-HEFT  Valsartan Heart Failure Trial; V-HeFT 
Vasodilator Heart Failure Trial I and II.
Figure 1. Cardiovascular disease mortality trends for males and females,
U.S., 1979 to 2000. Reprinted with permission from the American Heart
Association. Source: CDC/CHS. Black line  males; white line 
females.
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sive in prescribing medical therapy to their women patients
with HF when compared with the men. Furthermore, we
can no longer be complacent in attempting to stem the tide
by using measures of prevention, although efforts in this
arena have been traditionally focused on men. These pri-
mary prevention measures need to be implemented in
women as well. Extensive national campaigns, for example,
the American Heart Association “Women’s Heart Day,”
need to be supported by local communities. Other such
measures could include the dissemination of the Seventh
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pres-
sure (42) to the female lay public, programs that address
weight reduction coupled to information on exercise and
targeting of these programs to women groups, and
community-based smoking cessation programs, among oth-
ers. The advocates for dissemination of breast cancer aware-
ness have been highly successful in spreading their message.
Should we not do the same?
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